Table 1.
Baseline characteristics for ICPi-AKI
| Variable | ICPi-AKI (n=138) | Controls (n=276) | P Value |
|---|---|---|---|
| Age at ICPi initiation, yr | 67 (58–74) | 65 (56–73) | 0.36 |
| Female, n (%) | 55 (40) | 105 (38) | 0.75 |
| Race, n (%) | 0.15 | ||
| White | 116 (84) | 248 (91) | |
| Black | 10 (7) | 10 (4) | |
| Asian | 3 (2) | 5 (2) | |
| Comorbidities, n (%) | |||
| Hypertension | 77 (56) | 171 (62) | 0.24 |
| Diabetes | 23 (17) | 47 (17) | 1.00 |
| CHF | 3 (2) | 11 (4) | 0.40 |
| COPD | 6 (4) | 36 (13) | 0.005 |
| Cirrhosis | 2 (1) | 15 (5) | 0.06 |
| Baseline SCr, mg/dl | 0.91 (0.80–1.21) | 0.87 (0.70–1.06) | 0.002 |
| Baseline eGFR, ml/min | 72 (55–89) | 83 (63–99) | <0.001 |
| CKD, n (%) | 44 (32) | 56 (20) | 0.01 |
| CKD IV, n (%) | 9 (7) | 2 (1) | 0.001 |
| Autoimmune disease, n (%) | 17 (12) | 30 (11) | 0.74 |
| Malignancy, n (%) | 0.007 | ||
| Melanoma | 49 (36) | 82 (30) | |
| Lung | 36 (26) | 106 (38) | |
| Genitourinary | 23 (17) | 21 (8) | |
| Other | 30 (21) | 67 (24) | |
| PPI, n (%) | 75 (54) | 92 (33) | <0.001 |
| ICPia n (%) | |||
| Anti–CTLA-4b | 44 (32) | 48 (17) | 0.001 |
| Anti–PD-1c | 127 (92) | 250 (91) | 0.72 |
| Anti–PD-L1 | 10 (7) | 13 (4.7) | 0.36 |
| Combo anti–CTLA-4+anti–PD-1/PD-L1d | 39 (28) | 35 (13) | <0.001 |
Data are shown as median (IQR) and n (%). CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; IV, stage four; CTLA-4, cytotoxic T lymphocyte–associated antigen 4; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; Combo, combination.
a
Denotes all ICPis ever received.
b
Ipilimumab was the ICPi agent in 98% of those who received an anti–CTLA-4 antibody.
c
Nivolumab or pembrolizumab was the anti–PD-1 antibody in 49% and 42% of patients.
d
Ipilimumab/nivolumab was the combination therapy regimen in 75% of cases and 66% of controls.